Submitted by the Middlesex 3 Coalition
Recently at its 2023 Annual Meeting, the Middlesex 3 Coalition presented Ultragenyx Pharmaceutical Inc., a Bedford biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, and Chelmsford Town Manager Paul Cohen with their Private and Public Sector Community Impact Awards.
The Middlesex 3 Community Impact Awards were established to recognize an individual or company in the public and private sectors and thank them for their efforts over the last year to improve the economic vitality of the corridor. In giving Ultragenyx and Cohen these awards, Middlesex 3 wishes to demonstrate its gratitude and respect for the work they have done toward the continued growth of the thriving Middlesex region.
“Middlesex 3 is intensely focused on economic development within the corridor, and we place immense value in our partners both in the public and private sectors,” said Stephanie Cronin, Executive Director of the Middlesex 3 Coalition. “Only through close collaboration with exemplary organizations and individuals like Ultragenyx and Mr. Cohen can we continue in our mission to build a vigorous and diverse economy spanning a variety of industries, including life science, defense, IT, healthcare, and advanced manufacturing.”
Ultragenyx recently finished the construction of a 110,000-square-foot gene therapy manufacturing facility on a 10.7-acre site in Bedford. The new manufacturing facility represents the cutting edge of gene therapy manufacturing techniques, with the ability to produce treatments at a greater scale than ever before and modify and expand processes as need grows. Currently, Ultragenyx plans to hire 120 employees to staff the facility and will look to hire more workers from a range of skill levels and backgrounds in the coming years.
“Our partnership with Middlesex 3 has proven invaluable throughout the entire process of building our Bedford facility, from site selection and groundbreaking through construction and completion,” said Tom Lauzon, Vice President, Manufacturing-Gene Therapy at Ultragenyx who received the award on behalf of the company. “Being here in Bedford and working with the local educators, life science leaders, the Town of Bedford, the Bedford and Woburn Chambers of Commerce, and Middlesex 3 has allowed us to form strong bonds with the community. We remain committed to our mission and our continued work with this wonderful organization as we grow our presence in the region and across the state.”
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.